Literature DB >> 16469420

Peptide-binding assays and HLA II transgenic Abeta degrees mice are consistent and complementary tools for identifying HLA II-restricted peptides.

Stéphane Depil1, Gerhild Angyalosi, Olivier Moralès, Myriam Delacre, Nadira Delhem, Violaine François, Bertrand Georges, Juergen Hammer, Bernard Maillère, Claude Auriault, Véronique Pancré.   

Abstract

The identification of MHC class II-restricted peptides has become a priority for the development of peptide-based prophylactic and therapeutic vaccines. The aim of this study was to assess the correlations between peptide-binding assays on purified HLA II molecules and immunization of human HLA II transgenic mice deficient in murine class II molecules (Abeta degrees ). We used as models two MHC class II-restricted peptides, one derived from the HIV Nef regulatory protein (Nef (56-68)) and the other from the Schistosoma mansoni 28-kDa glutathione-S-transferase (Sm28GST (190-211)). High correlations were found between the two approaches, which showed that the Nef (56-68) and Sm28GST (190-211) peptides may represent promiscuous ligands for HLA-DQ and for HLA-DR molecules, respectively. We suggest a rational method based on the combination of peptide-binding assays and HLA II transgenic mice experiments as consistent and complementary tools for selecting T helper epitopes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16469420     DOI: 10.1016/j.vaccine.2005.11.048

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin.

Authors:  Katherine A Richards; Francisco A Chaves; Frederick R Krafcik; David J Topham; Christopher A Lazarski; Andrea J Sant
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

2.  Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.

Authors:  Kristina Blazanovic; Hongliang Zhao; Yoonjoo Choi; Wen Li; Regina S Salvat; Daniel C Osipovitch; Jennifer Fields; Leonard Moise; Brent L Berwin; Steven N Fiering; Chris Bailey-Kellogg; Karl E Griswold
Journal:  Mol Ther Methods Clin Dev       Date:  2015-06-17       Impact factor: 6.698

Review 3.  Challenges and approaches for the development of safer immunomodulatory biologics.

Authors:  Jean G Sathish; Swaminathan Sethu; Marie-Christine Bielsky; Lolke de Haan; Neil S French; Karthik Govindappa; James Green; Christopher E M Griffiths; Stephen Holgate; David Jones; Ian Kimber; Jonathan Moggs; Dean J Naisbitt; Munir Pirmohamed; Gabriele Reichmann; Jennifer Sims; Meena Subramanyam; Marque D Todd; Jan Willem Van Der Laan; Richard J Weaver; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 112.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.